Adicet Bio (ACET) Cash from Operations (2017 - 2026)

Adicet Bio has reported Cash from Operations for 10 years, with the latest figure at -$19.8 million in Q2 2026.

• On a quarterly basis, Cash from Operations rose 25.57% year-over-year to -$19.8 million in Q2 2026; TTM through Jun 2026 was -$84.5 million, a 13.87% increase from a year earlier, with the FY2025 full-year figure at -$95.2 million, down 3.1% from the prior year.
• Cash from Operations was -$19.8 million for Q2 2026 at Adicet Bio, up from -$21.5 million in the prior quarter.
• The five-year high for Cash from Operations was $4.1 million in Q1 2022, with the low at -$26.6 million in Q2 2025.
• Average Cash from Operations over 5 years is -$20.4 million, with a median of -$22.2 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations surged 127.1% in 2022, then tumbled 686.94% in 2023.
• Over 5 years, Cash from Operations stood at -$18.8 million in 2022, then fell by 24.68% to -$23.5 million in 2023, then decreased by 2.62% to -$24.1 million in 2024, then climbed by 13.24% to -$20.9 million in 2025, then gained by 5.19% to -$19.8 million in 2026.
• The last three Cash from Operations figures came in at -$19.8 million (Q2 2026), -$21.5 million (Q1 2026), and -$20.9 million (Q4 2025), per Business Quant data.